1-phenyl-3-methyl-4-benzoyl-5-pyrazolone, also known as **benzoylmethylpyrazolone** or **BMP**, is a versatile organic compound with a heterocyclic pyrazolone core structure. It finds application in various research areas due to its unique properties:
**Key Properties:**
* **Versatile Ligand:** BMP acts as a bidentate ligand, coordinating to metal ions through its nitrogen and oxygen atoms. This characteristic makes it suitable for forming complexes with a wide range of metals, including transition metals.
* **Spectrophotometric Properties:** BMP exhibits strong absorbance in the UV-Vis region, which is crucial for its use in analytical chemistry. It forms colored complexes with metal ions, allowing for spectrophotometric determination of their concentration.
* **Chelating Agent:** The presence of two coordinating atoms in BMP enables it to act as a chelating agent, trapping metal ions and preventing their interaction with other molecules.
* **Antioxidant Properties:** Studies suggest that BMP possesses antioxidant activity, potentially contributing to its role in various biological applications.
**Importance in Research:**
**1. Analytical Chemistry:**
* **Spectrophotometric analysis:** BMP is widely used as a reagent for the spectrophotometric determination of various metal ions, including iron, copper, nickel, and cobalt. Its high sensitivity and selectivity make it a valuable tool in environmental monitoring, food analysis, and pharmaceutical quality control.
* **Chromatographic analysis:** BMP derivatives are used in HPLC and GC for the separation and analysis of various compounds.
**2. Material Science:**
* **Metal coordination chemistry:** BMP is employed in the synthesis of various metal complexes with potential applications in catalysis, optoelectronics, and magnetism.
* **Polymer synthesis:** BMP derivatives are incorporated into polymer structures, leading to materials with enhanced properties such as thermal stability, conductivity, and optical properties.
**3. Biological Applications:**
* **Drug discovery:** BMP and its derivatives are explored as potential drug candidates for various ailments, including inflammation, cancer, and microbial infections. Their antioxidant and chelating properties contribute to their therapeutic potential.
* **Bioimaging:** BMP-based fluorescent probes are being developed for bioimaging applications, allowing for visualization of specific biological processes within cells and tissues.
**4. Environmental Chemistry:**
* **Heavy metal remediation:** BMP's chelating ability is utilized in the removal of heavy metal ions from wastewater and contaminated soil.
* **Environmental sensing:** BMP-based sensors are being developed for the detection of pollutants and environmental toxins in water and air.
**Overall, 1-phenyl-3-methyl-4-benzoyl-5-pyrazolone is a valuable compound with diverse applications in various research fields, owing to its unique chemical properties and versatility. Its importance lies in its potential for advancing knowledge in areas such as analytical chemistry, material science, biological chemistry, and environmental chemistry.**
1-phenyl-3-methyl-4-benzoyl-5-pyrazolone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 354929 |
CHEMBL ID | 3144705 |
SCHEMBL ID | 9288406 |
SCHEMBL ID | 12438890 |
MeSH ID | M0558048 |
Synonym |
---|
HMS3401G15 |
methanone, (5-hydroxy-3-methyl-1-phenyl-1h-pyrazol-4-yl)phenyl- |
(5-hydroxy-3-methyl-1-phenyl-pyrazol-4-yl)-phenyl-methanone |
smr000456549 |
(5-hydroxy-3-methyl-1-phenyl-1h-pyrazol-4-yl)(phenyl)methanone |
MLS000850531 |
MAYBRIDGE1_004190 |
SR-01000641901-1 |
(5-hydroxy-3-methyl-1-phenyl-1h-pyrazol-4-yl)phenylmethanone |
4-benzoyl-3-methyl-1-phenyl-1h-pyrazol-5-ol |
pyrazole 3 |
bdbm15716 |
STK008663 |
AKOS000275124 |
HMS553G12 |
4-benzoyl-5-methyl-2-phenyl-1h-pyrazol-3-one |
4-benzoyl-5-methyl-2-phenyl-1h-pyrazol-3(2h)-one |
AKOS015998989 |
CCG-52686 |
HMS2806N07 |
FT-0617632 |
STL367904 |
5-methyl-2-phenyl-4-(phenylcarbonyl)-1,2-dihydro-3h-pyrazol-3-one |
4-benzoyl-5-methyl-2-phenyl-2,3-dihydro-1h-pyrazol-3-one |
TD8140 |
64598-48-7 |
SCHEMBL9288406 |
SCHEMBL12438890 |
CHEMBL3144705 |
1-phenyl-3-methyl-4-benzoyl-5-pyrazolone |
1-phenyl-3-methyl-4-benzoylpyrazol-5-ol |
Z87002161 |
EN300-18658 |
BRD-K40293218-001-07-1 |
nsc-767309 |
nsc767309 |
BS-44044 |
(4z)-2,4-dihydro-4-(hydroxyphenylmethylene)-5-methyl-2-phenyl-3h-pyrazol-3-one |
127117-31-1 |
DTXSID701137518 |
DTXSID301321353 |
33064-14-1 |
Excerpt | Reference | Relevance |
---|---|---|
" These efforts identified 63 (RO3201195) as an orally bioavailable and highly selective inhibitor of p38 which was selected for advancement into Phase I clinical trials." | ( Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. Alfredson, T; Bertrand, J; Browner, MF; Clifford, K; Dalrymple, SA; Dunn, J; Freire-Moar, J; Goldstein, DM; Harris, S; La Fargue, J; Labadie, SS; Lapierre, JM; Larrabee, S; Li, F; McWeeney, D; Papp, E; Ramesha, C; Roberts, R; Rotstein, D; San Pablo, B; Sjogren, EB; So, OY; Talamas, FX; Tao, W; Trejo, A; Villasenor, A; Welch, M; Welch, T; Weller, P; Whiteley, PE; Young, K; Zipfel, S, 2006) | 0.33 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.3535 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 21.1446 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 25.1189 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 100.0000 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 15.8489 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 22.3872 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
geminin | Homo sapiens (human) | Potency | 20.7329 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0001 | 0.7266 | 7.8000 | AID1797419; AID261295 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
protein serine/threonine kinase activity | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
MAP kinase activity | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
MAP kinase kinase activity | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
protein binding | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
ATP binding | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
enzyme binding | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
protein phosphatase binding | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
mitogen-activated protein kinase p38 binding | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
NFAT protein binding | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
protein serine kinase activity | Mitogen-activated protein kinase 14 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID1797419 | In Vitro Kinase Assay from Article 10.1021/jm050736c: \\Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.\\ | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. |
AID261295 | Displacement of [33P] ATP from human recombinant active p38alpha | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. |
AID493017 | Wombat Data for BeliefDocking | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 6 (60.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.00) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |